"Ki-67 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
| Descriptor ID |
D019394
|
| MeSH Number(s) |
D12.776.660.625.500 D23.050.290.500 D23.101.140.400
|
| Concept/Terms |
Ki-67 Antigen- Ki-67 Antigen
- Antigen, Ki-67
- Ki 67 Antigen
- Antigen Ki-67
- Antigen Ki 67
- Ki-67, Antigen
- MIB-1 Antigen
- Antigen, MIB-1
- MIB 1 Antigen
- MIB-1 Protein
- MIB 1 Protein
- Antigen Ki67
- Ki67, Antigen
|
Below are MeSH descriptors whose meaning is more general than "Ki-67 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-67 Antigen".
This graph shows the total number of publications written about "Ki-67 Antigen" by people in this website by year, and whether "Ki-67 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 6 | 6 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 7 | 7 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 5 | 5 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 2 | 3 |
| 2017 | 2 | 2 | 4 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-67 Antigen" by people in Profiles.
-
TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present. Hum Pathol. 2024 04; 146:1-7.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Investigating the Spatial Distribution of Proliferating Cells in Primary Ovarian Cancers. Discov Med. 2024 Mar; 36(182):632-645.
-
Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs). Pathol Res Pract. 2024 Mar; 255:155163.
-
Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. Cancer Biol Med. 2024 Jan 03; 21(5).
-
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024 Mar; 35(3):293-301.
-
The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. Surgery. 2024 01; 175(1):80-89.
-
Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.
-
DNA Methylation Identifies Epigenetic Subtypes of Triple-Negative Breast Cancers With Distinct Clinicopathologic and Molecular Features. Mod Pathol. 2023 11; 36(11):100306.
-
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250.